Literature DB >> 16763521

HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies.

Robert A Domaoal1, Robert A Bambara, Lisa M Demeter.   

Abstract

We have previously demonstrated that nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutants have different levels of replication fitness relative to wild type; those with greater reductions in fitness are less likely to develop during therapy in patients. We have also found that reductions in rates of RNase H cleavage by mutant RTs correlate with reductions in fitness and that NNRTI-resistant RTs catalyze polymerization with a processivity similar to wild type. In this study, we evaluated the polymerase function of 3 clinically occurring NNRTI-resistant RTs (K103N, P236L, and V106A) in greater detail, under both pre-steady-state and steady-state conditions. The overall pathway of single-nucleotide incorporation was unchanged for the mutant RTs compared with wild type. In addition, the NNRTI-resistant mutants were each similar to wild type in rate of nucleotide incorporation (kpol), affinity for dGTP (Kd), and steady-state rate of polymerization (kss and kcat), using either RNA or DNA templates. These findings suggest that the close proximity of the NNRTI-resistance mutations to the polymerase active site does not affect the interactions of the enzyme with the incoming nucleotide or the primer-template sufficiently to affect polymerization and support the hypothesis that these reductions in RNase H activity contribute to reductions in replication fitness.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763521     DOI: 10.1097/01.qai.0000222288.90201.33

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.

Authors:  Jiong Wang; Robert A Bambara; Lisa M Demeter; Carrie Dykes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.

Authors:  Christine E Koval; Carrie Dykes; Jiong Wang; Lisa M Demeter
Journal:  Virology       Date:  2006-06-21       Impact factor: 3.616

3.  L74V increases the reverse transcriptase content of HIV-1 virions with non-nucleoside reverse transcriptase drug-resistant mutations L100I+K103N and K101E+G190S, which results in increased fitness.

Authors:  Jiong Wang; Dongge Li; Robert A Bambara; Hongmei Yang; Carrie Dykes
Journal:  J Gen Virol       Date:  2013-03-27       Impact factor: 3.891

4.  Reverse transcriptase backbone can alter the polymerization and RNase activities of non-nucleoside reverse transcriptase mutants K101E+G190S.

Authors:  Jiong Wang; Dongge Li; Robert A Bambara; Carrie Dykes
Journal:  J Gen Virol       Date:  2013-06-26       Impact factor: 3.891

5.  Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple.

Authors:  Francesca Razzolini; Francesco Saladini; Lisa Malincarne; Ilaria Vicenti; Nicola Palladino; Laura Romano; Daniela Francisci; Maurizio Zazzi
Journal:  J Clin Microbiol       Date:  2008-09-24       Impact factor: 5.948

Review 6.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

7.  A strategy to model nonmonotonic dose-response curve and estimate IC50.

Authors:  Hui Zhang; Jeanne Holden-Wiltse; Jiong Wang; Hua Liang
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.